Meeting
2023 ASCO Annual Meeting
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
Authors
Yusuke Okuma
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Yusuke Okuma , Kaoru Kubota , Mototsugu Shimokawa , Kana Hashimoto , Yosuke Kawashima , Hiroshi Wakui , Shuji Murakami , Kyoichi Okishio , Kenji Hayashihara , Yuichiro Ohe , Tomohiro Sakamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
jRCTs071200002
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9045)
DOI
10.1200/JCO.2023.41.16_suppl.9045
Abstract #
9045
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).
First Author: Myung-Ju Ahn
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2022 ASCO Annual Meeting
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
First Author: Hiroshige Yoshioka
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata